Select Page
Innovation Platform

NUNATAK BIOTECH

Startup - Founded in 2023Buenos Aires, Argentina
Nutrients Nitrogen relatedPhosphorus relatedOther nutrients
Technologies Biostimulants & Microbials

Nunatak Biotech is a biotechnology startup harnessing extremophilic microbes from Antarctica and other harsh environments to develop next-generation bioinputs for agriculture. Our microbial consortia are designed to improve crop performance under abiotic stress—such as salinity and drought—by enhancing resilience, nutrient uptake, and soil health.

We bridge the gap between chemical and biological solutions, offering scalable, compatible, and effective technologies for sustainable farming. Our R&D platform combines microbiology, plant science, and synthetic ecology to identify and formulate robust microbial communities tailored to specific crop and soil challenges.

Your IFA Innovation Platform Profile

What collaboration are we looking for?

We are seeking collaboration and support in the following areas:

Field validation and scale-up of our microbial bioinputs in diverse agroecological zones.

Regulatory guidance and market access strategies for international expansion.

Co-development partnerships with fertilizer or input companies to create integrated solutions combining biologicals and conventional products.

Investment and strategic support to accelerate product development and commercialization.

R&D collaboration for testing microbial consortia performance under abiotic stress (e.g., salinity, drought) and in synergy with existing fertilizers.

What solutions and opportunities are we offering?

We offer collaboration and support in the following areas:

Development of microbial solutions tailored to specific crops, soils, or stress conditions (e.g., salinity, drought).

Co-creation of bio-fertilizer or biostimulant products that are compatible with conventional inputs.

Microbial screening and formulation expertise using extremophiles from unique environments such as Antarctica.

Joint field trials and data generation to validate product performance and regulatory compliance.

Open innovation partnerships to integrate biologicals into broader sustainability and input strategies.

Additional geographies of business operation

Europe, North America

Maturity / funding

Pre-seed

Additional Information

Funding received ($) and name of funders

USD 280K

... of which equity investment

$275,000

... of which grants

$5,000

Awards received, and brief description of the award(s)

Awards and Recognitions – Nunatak Biotech

GridX Accelerator – Selected for the pre‑seed program and received first investment (Argentina)

IncuBAte Program – Gobierno de la Ciudad de Buenos Aires (Argentina)

SVG Ventures | THRIVE Global Accelerator – Selected among top agtech startups globally (USA)

RAÍCES Program – Eatable Adventures & ICEX (España)

ANII Support – Agencia Nacional de Investigación e Innovación (Uruguay)

Atento Capital – Latin America–Tulsa innovation bridge (USA)

G20‑LAND Initiative – Represented as a climate innovation startup at COP16

Green Solution Award – 2nd place winner (2024)

Startup Showcase at World Agri‑Tech South America – Exhibitor selected for the 2025 summit in São Paulo

Pitch Challenge – German Accelerator Agtech Challenge – Winner 2024

Expected opening of next investment round

Q4 2025

Expected funding sought from next investment round

USD 1.5M

Expected closing of next investment round

Q1/Q2 2026

Intellectual property & regulation

What is the IP status of your innovation(s)?

We are currently finalizing a provisional patent application to protect our core technology. Filing is planned in the short term as part of our IP strategy to safeguard our microbial consortia and their agricultural applications.

What regulatory approvals are you currently seeking, or have already been achieved?

We are currently pursuing two parallel regulatory pathways for our microbial bioinputs:

One under a framework that requires multi-season field validation trials, with an estimated approval timeline of approximately 2 years.

A second route that allows for faster registration without field trials, typically completed in around 6 months.

This dual approach enables us to accelerate initial market entry while building a robust validation pipeline for broader, long-term commercialization.

Contact details

Ms Julia Mensa Galoppo
CEO
+54 9 3516 19-9826
Download Pitch / Introduction deck